Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Andrew S. Epstein

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1808-3070; OpenAlex author ID A5083487197. Sources: ClinicalTrials.gov.

Their work

Papers
12 (first author 2, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 1 trial · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  2. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  3. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  4. Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.34269↗
  5. Prognostic value of the Memorial Sloan Kettering Prognostic Score in metastatic pancreatic adenocarcinoma. Last author DOI 10.1002/cncr.33420↗
  6. Reply to Nutritional support in pancreatic cancer. First author DOI 10.1002/cncr.32712↗
  7. Pancreatic cancer-A disease in need: Optimizing and integrating supportive care. First author DOI 10.1002/cncr.32423↗
  8. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adeno… Co-author DOI 10.1002/cncr.31218↗
  9. Identification of germline genetic mutations in patients with pancreatic cancer. Co-author DOI 10.1002/cncr.29664↗
  10. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Co-author DOI 10.1002/cncr.26600↗
  11. Communication and palliative care in a 64-year-old man with pancreatic adenocarcinoma. Co-author PMID 23077687↗
  12. A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. Co-author DOI 10.1007/s12029-010-9197-1↗

Trials 1

  1. Person-Centered Oncology Care and Choices (P-COCC): Piloting and Initial Randomized Testing of a Combined Values Narrative Interview and Video Education Advanc… Principal investigator NCT01912131↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 10 shared papers, 2011–2025 · strength 0.96
  2. Gordon Taylor Moffat · 2 shared papers, 2019–2020 · strength 0.35
  3. David Paul Kelsen · 5 shared papers, 2011–2022 · strength 0.27
  4. Anna M. Varghese · 2 shared papers, 2022–2025 · strength 0.27
  5. Wungki Park · 2 shared papers, 2022–2025 · strength 0.27
  6. Kenneth H. Yu · 3 shared papers, 2015–2022 · strength 0.22
  7. Marinela Capanu · 3 shared papers, 2012–2022 · strength 0.21
  8. Justin M. Lebenthal · 1 shared paper, 2021 · strength 0.16
  9. Maeve Aine Lowery · 4 shared papers, 2011–2018 · strength 0.16
  10. Benjamin D. Greenbaum · 1 shared paper, 2025 · strength 0.15
  11. Olca Baştürk · 1 shared paper, 2025 · strength 0.15
  12. Vinod P. Balachandran · 1 shared paper, 2025 · strength 0.15
  13. Taha Merghoub Merghoub · 1 shared paper, 2025 · strength 0.15
  14. Ryan Sugarman · 1 shared paper, 2025 · strength 0.15
  15. Jedd D. Wolchok · 1 shared paper, 2025 · strength 0.15
  16. Zachary M. Sethna · 1 shared paper, 2025 · strength 0.15
  17. Luis Alfonso Rojas · 1 shared paper, 2025 · strength 0.15
  18. Kevin C. Soares · 1 shared paper, 2025 · strength 0.15
  19. Özlem Türeci · 1 shared paper, 2025 · strength 0.15
  20. T. Peter Kingham · 1 shared paper, 2025 · strength 0.15
  21. Akihiro Ohmoto · 1 shared paper, 2025 · strength 0.15
  22. Michael Ian D'Angelica · 1 shared paper, 2025 · strength 0.15
  23. Ira Mellman · 1 shared paper, 2025 · strength 0.15
  24. Uğur Şahin · 1 shared paper, 2025 · strength 0.15
  25. Jeffrey A. Drebin · 1 shared paper, 2025 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.